

ICT 2025

29th International Congress on Thrombosis Porto, Portugal

6-8 November 2025 Sheraton Hotel



emltd2025.com



Committees

Organising Committee

João Morais, Portugal | ICT 2025 Chairperson

Luciana Gonçalves, Portugal | ICT 2025 Chairperson

Daniel Caldeira, Portugal

Filipe Gonçalves, Portugal

Francisco Araújo, Portugal

Miguel Barbosa, Portugal

Silvia Monteiro, Portugal

Teresa Padró, Espanha

Scientific Committee

Alexandros Tselepis, Greece

Ana Bronic, Croatia

Anna Falanga, Italy

Bianca Rocca, Italy

Bruna Gigante, Sweden

Cristina Gavina, Portugal

Désirée Coen Herak, Croatia

Diana Aguiar Sousa, Portugal

Eduardo Oliveira, Portugal

Gemma Vilhaur, Spain

Georgia Kaiafa, Geece

Gili Kenet, Israel

Gregor Tratar, Slovenia

Hrvoje Budincevic, Croatia

Ileana Desormais, France

Ismail Elalamy, France

Joana Liz Pimenta, Portugal

José Ramon Juanetey, Spain

Juan Tamargo, Spain

Lina Badimon, Spain

Mojca Bozic, Slovenia

Rafaelle De Caterina, Italy

Ricardo Fontes-Carvalho, Portugal

Rui Medeiros, Portugal

Sérgio Barroso, Portugal

Teresa Padró, Spain

Ton Lisman, The Netherlands

Vittorio Pengo, Italy

Faculty

Alexandros Tselepis, Greece

Ana Bronic, Croatia

Anna Falanga, Italy

Ana Luísa Areia, Portugal

Ana Teresa Timóteo, Portugal

Andrea Rubboli, Italy

Andrés Muñoz Martín, Spain

Ângelo Carneiro, Portugal

Bianca Rocca, Italy

Carlos Vasconcelos, Portugal

Christos Savopoulos, Greece

Cláudia Moreira Jorge, Portugal

Cristina Gavina, Portugal

Daniel Caldeira, Portugal

Daniel Ferreira, Portugal

Désirée Coen Herak, Croatia

Diana Aguiar de Sousa, Portugal

Diana Cibele Gonçalves, Portugal

Dimitrios Sagris, Greece

Eduardo Oliveira, Portugal

Elif G. Umit, Turkey

Erik Grove, Denmark

Ester Ferreira, Portugal

Eva Mingot, Spain

Filipa Bargado, Portugal

Filipe Gonçalves, Portugal

Francisco Araújo, Portugal

Francisco Moscoso Costa, Portugal

Georgia Kaiafa, Greece

Gilli Kenet, Israel

Gregor Tratar, Slovenia

Heleen van Ommen, The Netherlands

Hrvoje Budincevic, Croatia

Hugo ten Cate, The Netherlands

Ileana Desormais, France

Ismail Elalamy, France

Joana Liz Pimenta, Portugal

Joana Martins Pimenta, Portugal

João Morais, Portugal

João Sargento Freitas, Portugal

Joaquim Calado, Portugal

Jorge Ferreira, Portugal

José Luis Ferreiro, Spain

José Ramon Juanatey, Spain

Faculty

Juan Tamargo, Spain

Lídia Costa, Portugal

Lina Badimon, Spain

Luciana Gonçalves, Portugal

Maria João Carvalho, Portugal

Marijo Vodanović, Croatia

Miguel Barbosa, Portugal

Miguel Nobre Menezes, Portugal

Moa Simonsson, Sweden

Mojca Božič Mijovski, Slovenia

Nikolaos Kakaletsis, Greece

Nuno Farinha, Portugal

Omri Cohen, Israel

Raffaele De Caterina, Italy

Rita Calé, Portugal

Roberto Roncon, Portugal

Rui Medeiros, Portugal

Scott Kaatz, USA

Sérgio Barroso, Portugal

Sílvio Leal, Portugal

Simon de Meyer, Belgium

Sofia Teixeira, Portugal





Teresa Padró, Spain Teresa Sevivas, Portugal Tiago Taveira, Portugal Valéria Tavares, Portugal Vittorio Pengo, Italy Walter Ageno, Italy Yves Gruel, France

DAY 6 | MEETING ROOM A

14:00 | 14:30 Welcome address

14:30 | 16:00 Cancer Associated Thrombosis - I

- Cancer-associated thrombosis epidemiology
 Sérgio Barroso
- Risk assessment models for VTE in cancer patients
- Cancer-associated thrombosis and thombocytopenia -Therapeutic challenge | Gregor Tratar
- VTE and mortality in hematological malignancies Ismail Elalamy
- Treatment of CAT: role of Factor XI inhibitors
 Filipe Gonçalves

16:00 | 16:30 **Coffee break and poster exhibition**

16:30 | 18:00 Thrombophilias, genetic disorders

- Update on inherited thrombophilias | Francisco Araújo
- Adquired thrombophilias: the other side of the spectrum | Carlos Vasconcelos
- Coagulation and fertility: the role of thrombophilia
 Filipa Bargado
- Can DOACs play a role in inhererited thrombophilia?
 Ileana Desormais
- Thrombophilia: from phenotype to genotype Ismail Elalamy

18:00 | 18:30 Moderated Posters

ICT 2025

DAY 6 | MEETING ROOM B

14:30 | 16:00 **Mechanisms of thrombosis**

- Visceral adiposity and increased thrombotic risk. Is the next therapeutic target? | Teresa Padró
- Platelets in thrombosis and inflammation following trauma injuries | Ana Bronic
- Clonal hematopoiesis and the risk of thrombosis
 Elif G. Umit
- Innate immunity and neutrophil's role in atherothrombosis | Dimitrios Sagris

16:00 | 16:30 **Coffee break and poster exhibition**

16:30 | 18:00 From lytics up to mechanical thrombectomy

- Mechanical thrombectomy vs catheter-directed thrombolysis for venous thromboembolism
- Modern treatment of pulmonary embolism in high risk patients | Rita Calé
- Thrombolysis in acute ischemic stroke. An update Hrvoje Budincevic
- Mechanical thrombectomy with or without lytics in acute ischemic stroke | Ângelo Carneiro
- Composition of stroke thrombi | Simon de Meyer

18:00 | 18:30 Moderated Posters

DAY 7 | MEETING ROOM A

09:00 | 10:00 **Moderated posters** 10:00 | 11:00 **Joint Session EMLTD - Portuguese Association of** Thrombosis and Haemostasis Thrombotic diseases in childs and young adults Pediatric thrombosis: Why, when | Teresa Sevivas Thrombosis in pediatric ICU patients | Heleen van Ommen Use of DOACs in pediatric patients | Lídia Costa Thromboprophylaxis in children with cancer Nuno Farinha **Coffee break and poster exhibition** 11:00 | 11:30 **Joint Session EMLTD - Portuguese Association of** 11:30 | 13:00 **Thrombosis and Haemostasis** Women, hormones and pregnancy Thrombosis in pregnancy: mechanisms and underlying risk factors | Ana Luísa Areia Thrombophilia testing and thromboprophylaxis in the obstetric setting | Sofia Teixeira Anticoagulation therapy in pregnancy. Managing risks **Diana Cibele Gonçalves** Hormone therapy and thrombosis | Maria João Carvalho 13:00 | 14:00 **Lunch time and sponsored sessions**

DAY 7 | MEETING ROOM A

14:00 14:30	Keynote lecture: Anticoagulation Stewardship – A Call to Action Scott Kaatz
14:30 16:00	Cancer associated thrombosis - II
	Endothelial dysfunction in cancer
	Approach to tumoral thrombosis Joana Liz Pimenta
	Cancer-associated thrombosis and immune checkpoint inhibitors: update Miguel Barbosa
	Genetic markers of Cancer - associated thrombosis Valéria Tavares
	Thrombotic risk versus haemorrhagic risk - strategies Andrés Muñoz Martín
16:00 16:30	Coffee break and poster exhibition
16:30 17:30	Thrombotic risk in platelet disorders
	Immune thrombocytopenic purpura Eva Mingot
	Rapid determination of ADAMTS13 – implication for the prompt diagnosis of TTP Désirée Coen Herak
	Treatment options of immune and congenital TTP Marijo Vodanović
	Platelet function testing: update and future directions
17:30 18:30	Case based session
	Challenges in our daily clinical practice
18:30	EMLDT - General Assembly

DAY 7 | MEETING ROOM B

09:00 | 10:00 **Meet the scientist**What I'm doing on my research

10:00 | 11:00 Laboratory monitoring of haemostasis

- Inter-laboratory comparability of anti-Xa for measuring blood concentrations of oral anti-Xa inhibitors
 Mojca Božič Mijovski
- Global coagulation assays: is there a role in thrombosis risk evaluation
- Thrombin generation assay: from resarch to clinical use
 Désirée Coen Herak
- Lupus Anticoagulant: a puzzling laboratory test Vittorio Pengo

11:00 | 11:30 **Coffee break and poster exhibition**

11:30 | 13:00 Bleeding and hemorrhagic disorders

- Anemia and bleeding issues in women
- Novel treatments of bleeding disorders-are we increasing the risk of thrombosis? | Gilli Kenet
- How to resume anticoagulants after an episode of severe bleeding
- Antithrombotic therapy in patients at high bleeding risk
 Erik Grove
- High bleeding risk definition | Moa Simonsson

13:00 | 14:00 Lunch time and sponsored sessions

DAY 7 | MEETING ROOM B

14:00 | 14:30 **Keynote lecture: Cancer-associated thrombosis:** pathophysiology complexity | Rui Medeiros

14:30 | 16:00 News on antithrombotic therapy - I

- Factor XI inhibitors premises, promises and challenges
 Juan Tamargo
- Cardiogenic shock, a permanent challenge to antithrombotic therapy | Jorge Ferreira
- Stopping anticoagulation at the end of life
- Perioperative management of anticoagulant and antiplatelet therapy | Luciana Gonçalves
- How to handle high bleeding risk patients in the cath lab Andrea Rubboli

16:00 | 16:30 **Coffee break and poster exhibition**

16:30 | 17:30 Atrial fibrillation a good model to test antithrombotic strategies

- How to assess thromboembolic risk beyond classical risk scores? | Ana Teresa Timóteo
- Role of DOACs in patients with asymptomatic subclinical AF detected by device | Daniel Caldeira
- Antithrombotic treatment in ACS with coexisting atrial fibrillation | Raffaele De Caterina
- How to organize an integrative clinical patient care pathway | José Ramon Juanatey

17:30 | 18:00 Controversy: Factor XI inhibitors will replace DOACs in the near future

Pros and Cons

DAY 8 | MEETING ROOM A

08:30 | 09:30 **Oral Communications** 09:30 | 10:00 **Keynote lecture: Advances in cerebral venous** thrombosis | Diana Aquiar de Sousa **DVT** and pulmonary embolism 10:00 | 11:00 Diagnosis and treatment of splanchnic vein thrombosis **Walter Ageno** Prolonged treatment after VTE – which drugs to which patients? | Joana Martins Pimenta ACT for thrombosis of unusual sites - to DO(AC) or not to DO(AC) | Omri Cohen Thrombosis in multiple myeloma patients (use of PRISM SCORE) | Anna Falanga 11:00 | 11:30 Coffee break and poster exhibition **Joint Session EMLTD - Portuguese Society** 11:30 | 13:00 of Cardiology Old and new issues in Thrombocardiology Which is the optimal duration of dual antiplatelet therapy after ACS | João Morais Clinical effects of twice - versus once-daily low-dose aspirin | Bianca Rocca Antithrombotic management after non-coronary interventions | Eduardo Oliveira Prosthetic heart valves. What changed in terms of thrombotis risk? | Cristina Gavina Antithrombotic drugs for ACS in women Cláudia Moreira Jorge

DAY 8 | MEETING ROOM A

13:00 | 14:00 **Lunch time and sponsored sessions** 14:00 | 14:30 **Keynote lecture: Obesity, inflammation and** thrombosis | Lina Badimon 14:30 | 16:00 News on antithrombotic therapy - II Novel antiplatelet and anticoagulant drugs under clinical development | José Luis Ferreiro Is there still room for oral anticoagulants after ESUS in sinus rhythm? | João Sargento Freitas Aspirin for primary cardiovascular prevention. Is there still a role? | Nikolaos Kakaletsis Bentracimab significantly restored platelet function in patients taking Ticagrelor Antithrombotic strategies for patients with peripheral artery disease 16:00 **Closing Session**

DAY 8 | MEETING ROOM B

08:30 09:30	Oral Communications
09:30 10:00	Keynote lecture: Thrombosis, translational medicine and biomarkers research Hugo ten Cate
10:00 11:00	Immunothrombosis: molecular aspects and perspectives for therapy
	Complement and coagulation. Strangers or partners in crime? Georgia Kaiafa
	Trauma and sepsis induced coagulopaty Ana Bronic
	How to balance bleeding and thrombosis in patients on LVAD Roberto Roncon
	Anti PF4 antibodies: not only VITT and HIT Yves Gruel
11:00 11:30	Coffee break and poster exhibition
11:00 11:30 11:30 13:00	Coffee break and poster exhibition Topics to think, topics to react
	Topics to think, topics to react • Antiphospholipid syndrome. A continous challenges to
	 Topics to think, topics to react Antiphospholipid syndrome. A continous challenges to the clinicians Ester Ferreira The role of NETs in atherothrombosis
	 Topics to think, topics to react Antiphospholipid syndrome. A continous challenges to the clinicians Ester Ferreira The role of NETs in atherothrombosis Alexandros Tselepis D-dimer assay: over-testing in VTE?

DAY 8 | MEETING ROOM B

14:00 | 14:30 **Keynote lecture: Virus, vaccines and haemostasis:** looking through the evidence | Yves Gruel

14:30 | 16:00 The role of Artificial Inteligence (AI) and machine learning

- The AI co-pilot: a new ally against thrombotic diseases
 Daniel Ferreira
- Applications of Artificial Intelligence in the context of Thromboembolism | Tiago Taveira
- Al in atrial fibrillation: from early detection to precision therapy | Francisco Moscoso Costa
- Al applied to the diagnosis of coronary artery disease
 Miguel Nobre Menezes

Scientific Supporters



















Sponsors _____

SILVER SPONSOR



BRONZE SPONSORS



